About Aerovate Therapeutics
Aerovate Therapeutics is a company based in Boston (United States) founded in 2018 by Benjamin T Dake.. Aerovate Therapeutics has raised $75.82 million across 1 funding round from investors including Atlas Venture, Sofinnova and Osage University Partners. The company has 31 employees as of December 31, 2022. Aerovate Therapeutics offers products and services including AV-101. Aerovate Therapeutics operates in a competitive market with competitors including Actelion, Centessa Pharmaceuticals, Vivus, Biosion and CoTherix, among others.
- Headquarter Boston, United States
- Employees 31 as on 31 Dec, 2022
- Founders Benjamin T Dake
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Aerovate Therapeutics, Inc.
-
Annual Revenue
-
Net Profit
$-69.63 M8as on Dec 31, 2024
-
EBITDA
$-74.6 M8as on Dec 31, 2024
-
Total Equity Funding
$75.82 M (USD)
in 1 rounds
-
Latest Funding Round
$75.82 M (USD), Series A
Aug 07, 2020
-
Investors
Atlas Venture
& 2 more
-
Employee Count
31
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Aerovate Therapeutics
Aerovate Therapeutics offers a comprehensive portfolio of products and services, including AV-101. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Investigational inhaled formulation for treating rare cardiopulmonary diseases.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Aerovate Therapeutics
Aerovate Therapeutics has successfully raised a total of $75.82M through 1 strategic funding round. The most recent funding activity was a Series A round of $75.82 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series A — $75.8M
-
First Round
First Round
(07 Aug 2020)
- Investors Count 3
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug, 2020 | Amount | Series A - Aerovate Therapeutics | Valuation | Sofinnova Investments |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Aerovate Therapeutics
Aerovate Therapeutics has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Atlas Venture, Sofinnova and Osage University Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech funding, drug development support, and investment in life sciences.
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life science and biotechnology sectors
|
Founded Year | Domain | Location | |
|
Early- to growth-stage startups are targeted for venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Aerovate Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Aerovate Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Aerovate Therapeutics Comparisons
Competitors of Aerovate Therapeutics
Aerovate Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Actelion, Centessa Pharmaceuticals, Vivus, Biosion and CoTherix, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Innovative treatments for orphan diseases are discovered, developed, and commercialized.
|
|
| domain | founded_year | HQ Location |
Medicines for sleep-wake, neurological, neurodegenerative, and psychiatric disorders are developed.
|
|
| domain | founded_year | HQ Location |
Developer of therapeutic solutions for obesity and sexual health
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics are developed for treating various diseases.
|
|
| domain | founded_year | HQ Location |
Inhaled therapeutics for cardiopulmonary diseases were developed and licensed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Aerovate Therapeutics
Frequently Asked Questions about Aerovate Therapeutics
When was Aerovate Therapeutics founded?
Aerovate Therapeutics was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is Aerovate Therapeutics located?
Aerovate Therapeutics is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Is Aerovate Therapeutics a funded company?
Aerovate Therapeutics is a funded company, having raised a total of $75.82M across 1 funding round to date. The company's 1st funding round was a Series A of $75.82M, raised on Aug 07, 2020.
How many employees does Aerovate Therapeutics have?
As of Dec 31, 2022, the latest employee count at Aerovate Therapeutics is 31.
What does Aerovate Therapeutics do?
Aerovate Therapeutics was founded in 2018 and is based in Boston, United States. Focus is placed on the biotechnology sector, where inhaled therapies for rare cardiopulmonary diseases, including pulmonary arterial hypertension, are developed. Operations center on AV-101, an inhaled dry powder formulation of imatinib designed to target diseased lung tissues directly while minimizing systemic side effects. Clinical advancement of such treatments is pursued to address unmet needs in patient care.
Who are the top competitors of Aerovate Therapeutics?
Aerovate Therapeutics's top competitors include Actelion, Vivus and Centessa Pharmaceuticals.
What products or services does Aerovate Therapeutics offer?
Aerovate Therapeutics offers AV-101.
Who are Aerovate Therapeutics's investors?
Aerovate Therapeutics has 3 investors. Key investors include Atlas Venture, Sofinnova, and Osage University Partners.